Status:
SUSPENDED
Efficiency Study of S-Tenatoprazole-Na to Treat Erosive or Ulcerative Esophagitis
Lead Sponsor:
STEBA France
Conditions:
Esophagitis, Reflux
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
STU-Na belongs to the proton pump inhibitors (PPI), a group of drugs that reduce gastric acidity. PPI are used to treat acid related diseases like erosive or ulcerative esophagitis. This trial aims to...
Eligibility Criteria
Inclusion
- Male or female outpatients aged 18 to 75 years inclusive
- Symptomatic ulcerative or erosive esophagitis
- Presence of heartburn (daytime and/or nighttime).
- Understanding the study and agreeing to give a written informed consent
- Able to communicate well with the investigator him(her)self or his/her representatives
- Able and agreeing to comply with all study requirements
Exclusion
- gastrointestinal bleeding
- gastric or esophageal surgery
- Zollinger-Ellison syndrome
- primary esophageal motility disorders,
- esophageal stricture,
- inflammatory bowel disease,
- upper gastrointestinal malignancy,
- pancreatitis,
- malabsorption
- Barrett's esophagus (\> 3 cm)
- Severe disease/condition such as malignancy
- Hypersensitivity to PPIs
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
450 Patients enrolled
Trial Details
Trial ID
NCT00282555
Start Date
February 1 2006
Last Update
March 19 2008
Active Locations (17)
Enter a location and click search to find clinical trials sorted by distance.
1
Calgary, Alberta, Canada
2
Edmonton, Alberta, Canada
3
Abbottsford, British Columbia, Canada
4
Vancouver, British Columbia, Canada